E-resources
Peer reviewed
Open access
-
Ito, Shin; Takahama, Hiroyuki; Asakura, Masanori; Abe, Yukio; Ajioka, Masayoshi; Anzai, Toshihisa; Arikawa, Takuo; Hayashi, Takaharu; Higashino, Yorihiko; Hiramitsu, Shinya; Iwahashi, Noriaki; Izumi, Chisato; Kimura, Kazuo; Kinugawa, Koichiro; Kioka, Hidetaka; Lim, Young-Jae; Matsuoka, Ken; Matsuoka, Satoshi; Motoki, Hirohiko; Nakamura, Sunao; Nakayama, Takafumi; Nomura, Akihiro; Sasaoka, Taishi; Takiuchi, Shin; Toyoda, Shigeru; Ueda, Tomoya; Watanabe, Tetsuya; Yamada, Akira; Yamamoto, Masayoshi; Sozu, Takashi; Kitakaze, Masafumi
Scientific reports, 08/2023, Volume: 13, Issue: 1Journal Article
Characterized by ventricular and vascular stiffness, heart failure with preserved ejection fraction (HFpEF) has led to high morbidity and mortality. As azilsartan is an angiotensin receptor blocker with the highest myocardial and vascular affinities, azilsartan may improve the left ventricular (LV) diastolic function in patients with hypertension and either HFpEF or HF with mildly reduced ejection fraction (HFmrEF) more than candesartan. In this randomized, open-label trial, we randomly assigned 193 hypertensive patients with HF and LV ejection fraction ≥ 45% to 20 mg of azilsartan (n = 95) or 8 mg of candesartan (n = 98), once daily for 48 weeks. After the initiation of treatment, changes in the doses of the study drugs were permitted based on the patient's conditions, including blood pressure (median dose at 48 weeks: azilsartan 20.0 mg/day, candesartan 8.0 mg/day). The primary endpoint was the baseline-adjusted change in the ratio of peak early diastolic transmitral flow velocity (E) to early diastolic mitral annular velocity (e') (E/e'). Adjusted least-squares mean (LSM) change in E/e' was - 0.8 (95% confidence interval CI - 1.49 to - 0.04) in the azilsartan group and 0.2 (95% CI - 0.49 to 0.94) in the candesartan group, providing the LSM differences of - 1.0 (95% CI - 2.01 to 0.03, P = 0.057). The median change in left atrial volume index was - 2.7 mL/m with azilsartan vs 1.4 mL/m with candesartan (P = 0.091). The frequency of adverse events related to hypotension and hyperkalemia did not differ between the groups. The current study did not provide strong evidence that azilsartan improves LV diastolic dysfunction, and further confirmatory study is required.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.